Abstract
Prolonged exposure of cultured hippocampal slices to CX614 [2H,3H,6aH-pyrrolidino[2″,1″-3′,2′]1,3-oxazino[6′,5′-5,4]-benzo[e]1,4-dioxan 10-one], a positive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAr) modulator, decreases receptor response to synaptic stimulation, an effect that could reflect reduced receptor expression. The present study investigates this down-regulation and its underlying mechanisms using cultured rat hippocampal slices. Chronic treatment with CX614 gradually reduced levels of glutamate receptor (GluR)1 and GluR2/3 AMPAr subunits and of their anchoring proteins synapse-associated protein 97 (SAP97) and glutamate receptor interacting protein 1 (GRIP1) through 48 h. Decline in SAP97 and GRIP1 levels was associated with increased abundance of lower molecular weight bands, suggesting degradation of these proteins. CX614 effects were partially reversible after drug removal. GluR1 and GluR2/3 down-regulation and their slow recovery were associated with similar changes in SAP97 and GRIP1 levels. Treatment with CX614 for 48 h significantly reduced AMPAr mRNA levels in hippocampus, whereas 8-h exposure did not. Blockade of ionotropic glutamate receptors prevented CX614-induced decrease in AMPAr subunits and mRNA, with regional selectivity, although an AMPAr blocker was more efficacious than an N-methyl-d-aspartate receptor blocker. Blockade of calpain activity reduced CX614-induced degradation of SAP97 and GRIP1 and prevented decreases in AMPAr subunit but not mRNA levels. Treatment with CX614 alone or in combination with glutamate receptor blockers or calpain inhibitor III did not modify lactate dehydrogenase release into culture medium, implying the absence of cell toxicity. We conclude that CX614-induced AMPAr protein loss is primarily mediated by AMPAr activation and involves calpain-dependent proteolysis of SAP97 and GRIP1. CX614-induced suppression of AMPAr gene expression is, however, calpain-independent, and all these effects are not associated with cell damage.
Footnotes
-
This work was supported by National Institute of Neurological Disorders and Stroke Grant P01NS045260-01A1 (to C.M.G.). Portions of this work have been presented as meeting abstracts (Jourdi et al., Program 895.6. 2003 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, DC, 2003 Online; Jourdi et al., Program 50.16. 2004 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, DC, 2004 Online).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.083873.
-
ABBREVIATIONS: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AMPAr, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor(s); LTP, long-term potentiation; LTD, long-term depression; PDZ, PSD-95/Dlg/ZO-1; SAP97, synapse-associated protein 97; PSD-95, postsynaptic density protein 95; GRIP1, glutamate receptor interacting protein 1; NMDA, N-methyl-d-aspartate; BDNF, brain-derived neurotrophic factor; GluR, glutamate receptor; CX614, [2H,3H,6aH-pyrrolidino[2″,1″-3′,2′]1,3-oxazino[6′,5′-5,4]benzo[e]1,4-dioxan 10-one]; AP-5, 2-amino-5-phosphonopentanoic acid, CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; PB, phosphate buffer; TBS-T, Tris-buffered saline-Tween 20; LDH, lactate dehydrogenase; DMSO, dimethyl sulfoxide; ANOVA, analysis of variance; NMDAr, N-methyl-d-aspartate receptor.
- Received January 17, 2005.
- Accepted March 18, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|